Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol

INTRODUCTION: Empagliflozin is an SGLT-2 inhibitor (SGLT-2i) which belongs to a new class of hypoglycemic drugs with the unique property of decreasing blood glucose independently from insulin, through an increase in glycosuria. In addition to decreasing cardiovascular morbidity and mortality, empagl...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Adv Ther
Asıl Yazarlar: Muller, Marie-Eve, Pruijm, Menno, Bonny, Olivier, Burnier, Michel, Zanchi, Anne
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Healthcare 2018
Konular:
Study Protocol
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6015115/
https://ncbi.nlm.nih.gov/pubmed/29802538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-018-0708-y
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller